In this episode, TRC Healthcare editor, Vickie Danaher, PharmD, discusses recently approved drug formulations that bring fresh options—and new challenges—to the pharmacy counter.

From Arbli, the first ready-to-use losartan suspension, to Emrosi, a low-dose minocycline for rosacea, and Opipza, an oral film version of aripiprazole, we’ll walk through what makes each product unique and what pharmacy teams should watch for. We also cover HemiClor, a 12.5 mg chlorthalidone tablet that may help patients avoid splitting unscored tabs, Neffy, a needle-free epinephrine nasal spray now available in a pediatric strength, and wrap up with biosimilar updates on Merilog and Omlyclo.

This is an excerpt from our June 2025 Pharmacy Essential Updates continuing education webinar series.

The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

• Article: Watch for New Twists to Older Medications
• Chart: Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
• Chart: Treatments for Rosacea
• Chart: Comparison of Commonly Used Diuretics
• Chart: Comparison of Atypical Antipsychotics
• Chart: Emergency Epinephrine Devices
• Chart: Facts About Biosimilars

Use code cc1025 at checkout for 10% off a new subscription.

Send us a text

****

Join the National Community Pharmacists Associations’ Annual Convention (NCPA) in New Orleans October 18-21st: https://bit.ly/ncpameeting25

****

If you’re not yet a subscriber, find out more about our product offerings at trchealthcare.com.

Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

You can also reach out to provide feedback or make suggestions by emailing us at [email protected].